parkinson's disease triple agonist glp-1 gip glucagon clinical trial The Incretin Impact: a new era parkinson's disease triple agonist glp-1

Research shows that nearly 90% of people with type 2 diabetes also struggle with their weight, and these medications solve both problems at once

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

Molecular communications in the gutbrain axis, between the central nervous system and the gastrointestinal tract, are critical for maintaining healthy brain function, particularly in aging

However, renal effects of GLP-1 in heart failure (HF) has not been elucidated